Browse the corpus

©2013 UpToDate ® Print Email Adenocarcinoma histologic molecular radiologic subtypes Histological subtype predominant Molecular features CT scan appearance Nonmucinous adenocarcinoma in situ and minimally invasive adenocarcinoma TTF-1 + (100 percent) GGN, part-solid nodule EGFR mutation never smokers: 10-30 percent KRAS mutation smokers: 10-30 percent Lepidic (nonmucinous) TTF-1 + (100 percent) Part solid nodule EGFR mutation never smokers: 10-30 percent GGN or solid nodule EGFR amplification: 20-50 percent KRAS mutation smokers: 10 percent BRAF mutations: 5 percent Papillary TTF-1 + (90-100 percent) Solid nodule EGFR mutation: 10-30 percent EGFR amplification: 20-50 percent KRAS mutation 3 percent (lack of KRAS) ERBB2 mutations: 3 percent p53 mutations: 30 percent BRAF mutations: 5 percent Acinar TTF-1 + or - Solid nodule KRAS mutation in smokers (20 percent) EGFR mutations <10 percent nonsmokers EGFR amplification: 10 percent EML4/ALK translocation: >5 percent P53 mutations: 40 percent Micropapillary KRAS mutations (33 percent) Unknown EGFR mutations (20 percent) BRAF mutations (20 percent) Solid TTF-1 (70 percent) Solid MUC1 positive KRAS mutation smokers: 10-30 percent EGFR mutation never smokers: 10-30 percent EGFR amplification: 20-50 percent EML4/ALK translocation >5 percent p53 mutation: 50 percent LRP1B mutations INHBA mutations Invasive mucinous adenocarcinoma TTF-1 (0-33 percent positive) Consolidation, air bronchograms; less often GGO KRAS mutation: 80-100 percent No EGFR mutation MUC5+ MUC6+ MUC2+ EGFR: epidermal growth factor receptor; GGN: ground-glass nodule; GGO: ground-glass opacity; TTF: thyroid transcription factor. Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright © 2011 Lippincott Williams & Wilkins.